These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24078291)

  • 1. A single centre experience of active surveillance as management strategy for low-risk prostate cancer in Ireland.
    Forde JC; Daly PJ; White S; Morrin M; Smyth GP; O'Neill BD; Power RE
    Ir J Med Sci; 2014 Sep; 183(3):377-82. PubMed ID: 24078291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Feasibility study: watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression.
    Choo R; Klotz L; Danjoux C; Morton GC; DeBoer G; Szumacher E; Fleshner N; Bunting P; Hruby G
    J Urol; 2002 Apr; 167(4):1664-9. PubMed ID: 11912384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years.
    Goldberg H; Klaassen Z; Chandrasekar T; Wallis CJD; Toi A; Sayyid R; Bhindi B; Nesbitt M; Evans A; van der Kwast T; Sweet J; Perlis N; Hamilton RJ; Kulkarni GS; Finelli A; Zlotta A; Fleshner N
    J Urol; 2018 Nov; 200(5):1056-1061. PubMed ID: 29758220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
    Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
    BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Audit of rapid access introduction reveals high prevalence of prostate cancer in Western Region.
    Bolton EM; Kelly BD; Quinlan MR; D'Arcy FT; Azar M; Dowling CM; Power M; McCarthy P; Roche C; Walsh K; Rogers E; Durkan GC
    Ir J Med Sci; 2014 Jun; 183(2):173-9. PubMed ID: 23868288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.
    Ha JY; Shin TJ; Jung W; Kim BH; Park CH; Kim CI
    Investig Clin Urol; 2017 May; 58(3):164-170. PubMed ID: 28480341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer.
    Loeb S; Berglund A; Stattin P
    J Urol; 2013 Nov; 190(5):1742-9. PubMed ID: 23727309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
    Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
    BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
    Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
    Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort.
    Marzouk K; Assel M; Ehdaie B; Vickers A
    J Urol; 2018 Dec; 200(6):1250-1255. PubMed ID: 29886089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active surveillance can reduce overtreatment in patients with low-risk prostate cancer.
    Thomsen FB; Røder MA; Hvarness H; Iversen P; Brasso K
    Dan Med J; 2013 Feb; 60(2):A4575. PubMed ID: 23461989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
    Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
    J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density.
    Umbehr MH; Platz EA; Peskoe SB; Bhavsar NA; Epstein JI; Landis P; Partin AW; Carter HB
    BJU Int; 2014 Apr; 113(4):561-7. PubMed ID: 23746233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.
    Aminsharifi A; Simon R; Polascik TJ; Robertson CN; Sudan DL; Collins BH; Moul JW
    J Urol; 2019 Sep; 202(3):469-474. PubMed ID: 30835631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA; Konety BR; Cowan JE; Shinohara K; Stauf F; Cooperberg MR; Meng MV; Kane CJ; Perez N; Master VA; Carroll PR
    Cancer; 2008 Jun; 112(12):2664-70. PubMed ID: 18433013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active surveillance: the Canadian experience.
    Klotz L
    Curr Opin Urol; 2012 May; 22(3):222-30. PubMed ID: 22453335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between initial PSA density with future PSA kinetics and repeat biopsies in men with prostate cancer on active surveillance.
    Kotb AF; Tanguay S; Luz MA; Kassouf W; Aprikian AG
    Prostate Cancer Prostatic Dis; 2011 Mar; 14(1):53-7. PubMed ID: 20938463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.